Overview
- WHO’s Technical Advisory Group on Virus Evolution continues to list XFG as a Variant Under Monitoring due to its rapid expansion but low additional risk
- First identified on January 27, 2025, XFG arose from recombination of Omicron sublineages LF.7 and LP.8.1.2 and has been detected in at least 38 countries
- Clinical data indicate XFG infections do not increase hospitalizations or severe disease and often include typical COVID-19 symptoms plus transient hoarseness
- Declining booster coverage and waning population immunity are cited as key factors behind XFG’s rise to about 48% of global sequences by July 20
- Mexico has yet to report any confirmed XFG cases as WHO-led genomic surveillance continues